Orion Pharma (DHA:ORIONPHARM) Owner Earnings per Share (TTM): -7.33 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

DHA:ORIONPHARM Orion Pharma Ltd DHA:ORIONPHARM
72 GF Score
Price BDT29.40
GF Value BDT20.00
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Orion Pharma Owner Earnings per Share (TTM)?

Orion Pharma DHA:ORIONPHARM +2.08% 72 Owner Earnings per Share (TTM) is -7.33 as of Mar. 2026. GuruFocus rates DHA:ORIONPHARM with a GF Score™ of 72/100 and a GF Value™ of BDT20.00 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 163 Utilities - Independent Power Producers companies, Orion Pharma ranks worse than 613496.32% on this metric.

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Orion Pharma's Owner Earnings per Share (TTM) ended in Mar. 2026 was BDT-7.33. It's Price-to-Owner-Earnings ratio for today is 0.


The historical rank and industry rank for Orion Pharma's Owner Earnings per Share (TTM) or its related term are showing as below:


During the past 12 years, the highest Price-to-Owner-Earnings ratio of Orion Pharma was 6076.47. The lowest was 22.76. And the median was 127.19.


DHA:ORIONPHARM's Price-to-Owner-Earnings is not ranked *
in the Utilities - Independent Power Producers industry.
Industry Median: 12.4
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

Orion Pharma's Earnings per Share (Diluted) for the three months ended in Mar. 2026 was BDT-0.65. Its Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was BDT-3.11. It's PE Ratio (TTM) ratio for today is At Loss.

Orion Pharma's EPS without NRI for the three months ended in Mar. 2026 was BDT-0.65. Its EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 was BDT-3.11. It's PE Ratio without NRI ratio for today is At Loss.


Be Aware

Assumption: Companies usually do not report maintenance capital expenditures and growth capital expenditures separately. Here we use estimated numbers and average them over 5 years. The method to estimate maintenance capital expenditures can be found in above part 4.

Note: GuruFocus' Change In Working Capital is provided by Morningstar. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement from original financial report. And it includes non-current parts of assets and liabilities.


Orion Pharma Owner Earnings per Share (TTM) Related Terms


Orion Pharma Owner Earnings per Share (TTM) Historical Data

* Premium members only.

The historical data trend for Orion Pharma's Owner Earnings per Share (TTM) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Orion Pharma Owner Earnings per Share (TTM) Chart

Orion Pharma Annual Data
Trend Dec14 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Owner Earnings per Share (TTM)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.37 -0.77 0.23 -4.93 -6.28

Orion Pharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Owner Earnings per Share (TTM) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4.39 -6.28 -7.38 -7.74 -7.33

DHA:ORIONPHARM vs CEG, VST, NRG: Owner Earnings per Share (TTM) Comparison

For the Utilities - Independent Power Producers subindustry, Orion Pharma's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Orion Pharma Price-to-Owner-Earnings vs Utilities - Independent Power Producers Industry

For the Utilities - Independent Power Producers industry and Utilities sector, Orion Pharma's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Orion Pharma's Price-to-Owner-Earnings falls into.


DHA:ORIONPHARM
72GF Score
Orion Pharma Ltd DHA:ORIONPHARM
Owner Earnings per Share (TTM) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Orion Pharma Owner Earnings per Share (TTM) Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

To make it simple, then you will have:

Owner Earnings per Share (TTM) = (Net Income + Depreciation, Depletion and Amortization + Change In Deferred Tax - 5Y Average of Maintenance Capital Expenditure + Change In Working Capital) / Shares Outstanding (Diluted Average)

Orion Pharma's Owner Earnings per Share (TTM) Calculation:

TTM / Last Quarter Average of Last 20 Quarters
Net Income -727
Depreciation, Depletion and Amortization 576
Change In Deferred Tax 0
5Y Average of Maintenance Capital Expenditure 1,993
Change In Working Capital 429
Shares Outstanding (Diluted Average) 234

1. Start with "Net Income" from income statement. Orion Pharma's Net Income for the trailing twelve months (TTM) ended in Mar. 2026 was BDT-727 Mil.

2. "Depreciation, Depletion and Amortization" is from cashflow statement. Orion Pharma's Depreciation, Depletion and Amortization for the trailing twelve months (TTM) ended in Mar. 2026 was BDT576 Mil. This needs to be added back because company does not actually need to pay cash for it. It is a non-cash item.

3. Other non-cash charges usually include "Stock Based Compensation" and "Change In Deferred Tax":
However, to be conservative, GuruFocus will not add Stock Based Compensation back to net income. Orion Pharma's Change In Deferred Tax for the trailing twelve months (TTM) ended in Mar. 2026 was BDT0 Mil.

4. Average maintenance capital expenditure over a business/industry cycle: 5-Year Average Maintenance Capital Expenditure = BDT1,993 Mil

It is usually best to take a long-term average of maintenance capital expenditure. Ideally this would be as long as 10 years and include at least one economic downturn. However, since many companies do not have as long as 10-year history, here GuruFocus uses the latest 5 years data to do the calculation. To smooth out unusual years but reflect recent developments, we take an average of the 5 year maintenance capital expenditure.

The following shows how to get maintenance capital expenditure.

First, calculate the revenue change regarding to the previous quarter. If the revenue decreased from the previous quarter, then the Maintenance Capital Expenditure = Capital Expenditure (positive).
Second, if the revenue increased from the previous quarter, then calculate the percentage of Net PPE as of corresponding Revenue.
Growth Capital Expenditure = Percentage of Property, Plant and Equipment as of corresponding Revenue * Revenue Increase
Third, calculate Capital Expenditure (positive) - Growth Capital Expenditure.
If [Capital Expenditure (positive) - Growth Capital Expenditure] was negative, then the Maintenance Capital Expenditure = Capital Expenditure (positive).
If [Capital Expenditure (positive) - Growth Capital Expenditure] was positive, then the Maintenance Capital Expenditure = Capital Expenditure (positive) - Growth Capital Expenditure.
Fourth, get the average of the 5 years maintenance capital expenditure.

Orion Pharma's 5-Year Average Maintenance Capital Expenditure = BDT1,993 Mil

5. "Change In Working Capital" is from cashflow statement. Orion Pharma's Change In Working Capital for the trailing twelve months (TTM) ended in Mar. 2026 was BDT429 Mil.
Note: GuruFocus' Change in Working Capital is provided by Morningstar. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement from original financial report. And sometimes it includes non-current parts of assets and liabilities.

6. Orion Pharma's Shares Outstanding (Diluted Average) for the months ended in Mar. 2026 was 234.000 Mil.

Orion Pharma's Onwer Earnings Per Share for Mar. 2026 is calculated as:

Owner Earnings per Share (TTM)
=( Net Income+Depreciation, Depletion and Amortization+Change In Deferred Tax
=( -726.87 +576.042+0
-5Y Avg of Maintenance CAPEX+Change In Working Capital )/Shares Outstanding (Diluted Average)
-1993.1517843794+428.76)/234.000
=-7.33

Price-to-Owner-Earnings=Current Price/Owner Earnings per Share (TTM)
=29.40/-7.33
=0

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Owner Earnings per Share (TTM) of -7.33 mean?
Orion Pharma (DHA:ORIONPHARM) has a Owner Earnings per Share (TTM) of -7.33 as of Mar. 2026. Warren Buffett defined owner earnings as reported earnings plus depreciation less average maintenance capital expenditure. View historical data on Orion Pharma. Over the past decade, Orion Pharma's Owner Earnings per Share (TTM) has ranged from 22.76 to 6,076.47. According to the industry distribution chart, Orion Pharma ranks #999999 out of 163 companies in the Utilities - Independent Power Producers industry.
Is Orion Pharma's Owner Earnings per Share (TTM) too high?
Orion Pharma's current Owner Earnings per Share (TTM) is -7.33. Over the past 10 years, this metric has ranged from a low of 22.76 to a high of 6,076.47. Based on the distribution chart, Orion Pharma ranks #999999 out of 163 companies in the Utilities - Independent Power Producers industry, which is in the bottom quartile relative to peers. Overall, Orion Pharma has a GF Score™ of 72/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Orion Pharma's Owner Earnings per Share (TTM) compare to CEG and VST?
According to the Utilities - Independent Power Producers industry distribution chart, Orion Pharma ranks #999999 out of 163 companies for Owner Earnings per Share (TTM). This places Orion Pharma in the lower half of its industry. The industry median Owner Earnings per Share (TTM) is 12.40. Historically, Orion Pharma's own Owner Earnings per Share (TTM) has ranged from 22.76 to 6,076.47 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Owner Earnings per Share (TTM) for an Utilities - Independent Power Producers company?
The median Owner Earnings per Share (TTM) among Utilities - Independent Power Producers companies is 12.40, based on 163 companies in the industry. Companies in the top quartile (top 25%) have a Owner Earnings per Share (TTM) significantly above this median, while those in the bottom quartile fall well below. However, Owner Earnings per Share (TTM) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Owner Earnings per Share (TTM) mean?
A high Owner Earnings per Share (TTM) can signal that a stock is expensive relative to its fundamentals. Warren Buffett defined owner earnings as reported earnings plus depreciation less average maintenance capital expenditure. View historical data on Orion Pharma. For the Utilities - Independent Power Producers industry, the median Owner Earnings per Share (TTM) is 12.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Orion Pharma's current Owner Earnings per Share (TTM) is -7.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orion Pharma stock overvalued right now?
Based on GuruFocus' analysis, Orion Pharma (DHA:ORIONPHARM) is currently considered Significantly Overvalued. The stock's GF Value™ is BDT20.00, compared to a current price of BDT29.40 — trading 47% above its estimated fair value. The current Owner Earnings per Share (TTM) is -7.33. Orion Pharma's overall GF Score™ is 72/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Owner Earnings per Share (TTM) calculated?
Owner Earnings per Share (TTM) is calculated from a company's financial statements. For Orion Pharma (DHA:ORIONPHARM), the current Owner Earnings per Share (TTM) is -7.33 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Orion Pharma (DHA:ORIONPHARM) Overvalued in 2026?

Based on GuruFocus' analysis, Orion Pharma stock appears to be overvalued. The current stock price of BDT29.40 is trading 47% above its estimated GF Value™ of BDT20.00. GuruFocus considers Orion Pharma to be Significantly Overvalued.

Key valuation signals for DHA:ORIONPHARM:

  • Owner Earnings per Share (TTM): -7.33
  • GF Value™: BDT20.00 vs. price of BDT29.40 (47% above fair value)
  • GF Score™: 72/100 with 8 warning signs

No single metric tells the full story. See the DHA:ORIONPHARM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Orion Pharma Business Description

Address 153-154 Tejgaon Industrial Area, Orion House, Dhaka, BGD, 1208
Orion Pharma Ltd is a pharmaceutical company engaged in the creation and discovery, development, manufacturing, and marketing of pharmaceutical products, including vaccines and health-related consumer products. The company produces diversified dosage forms such as tablets, capsules, syrups, solutions, suspensions, powder for suspensions, creams, ointments, and injections under therapeutic categories including cardiovascular, antiulcerant, antiasthmatic, antihistamine, NSAIDs, antibiotic, antifungal, laxatives, anticancer, vitamins, and minerals. In addition, the company is involved in power generation activities and generates maximum revenue from pharmaceutical activities. The group principally carries out its business operations and markets its products in Bangladesh.
72GF Score

Get the complete analysis for DHA:ORIONPHARM

Owner Earnings per Share (TTM) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

BDT29.40
Price
BDT20.00
GF Value